Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It will merger into EAIN. The name of EAIN changed in the Nevada SOS to it yesterday
Mirror Biologics, Inc.
https://esos.nv.gov/EntitySearch/BusinessInformation?businessid=337568
$EAIN Merger coming with Mirror Biologics, Inc on 10/29/2020
NVSOS Name changes happened today
https://www.fundable.com/mirror-biologics
Active Clinical Trial:
https://clinicaltrials.gov/ct2/show/NCT04441047?term=NCT04441047&draw=2&rank=1
Latest news:
Immunovative Therapies and Mirror Biologics Announce US FDA Clearance of a Universal Anti-Viral Vaccine Phase I/II Clinical Trial for Healthy Elderly Adults
https://www.prnewswire.com/il/news-releases/immunovative-therapies-and-mirror-biologics-announce-us-fda-clearance-of-a-universal-anti-viral-vaccine-phase-iii-clinical-trial-for-healthy-elderly-adults-301081793.html
JERUSALEM and PHOENIX, June 23, 2020 /PRNewswire/ -- Mirror Biologics, Inc. (Phoenix, AZ), the commercial development arm of Immunovative Therapies, Ltd. (Jerusalem, IL) (together "the Company"), a clinical-stage company specialized in the development, manufacturing and clinical translation of next-generation immunotherapy drugs where the active ingredients are living immune cells, today announced that the U.S. Food and Drug Administration (FDA) has cleared our Phase I/II universal virus vaccine clinical trial under the Company's second active Investigational New Drug (IND) application enabling use of the Company's lead experimental drug, AlloStim®, for testing as an anti-viral prophylaxis drug.
AlloStim® is an off-the-shelf, non-genetically manipulated, patented living immune cell with multiple immunodulatory properties, currently being tested under a separate IND as a therapeutic vaccine for chemotherapy-refractory metastatic cancers.
This Phase I/II trial is believed to be the first anti-viral vaccine in clinical development that is specifically targeted to protect the elderly. The elderly are the most vulnerable in our society to the severe and lethal effects of respiratory viral infections which cause disease complications such as pneumonia. Pneumonia is the single most common cause of death from infectious disease in those over 65 years old. The chance that a COVID-19 patient will develop symptoms severe enough to require hospitalization and respiratory support rises sharply with age and the death rate due to COVID-19 is disproportionately higher in our senior citizens.
Dr. Michael Har-Noy, founder and CEO stated: "We are pleased to have FDA clearance of our novel universal viral vaccine clinical trial targeted to healthy adults over 65 years old. There is a large unmet need to protect the elderly from the devastating effects of respiratory viral infection. If we can protect the elderly from COVID-19, economies can open safely and herd immunity can be allowed to develop without an alarming increase in death rate. Even if a COVID-19 vaccine is developed, it is likely, as with influenza vaccines, that it will be less effective in the elderly where protection is most needed. In addition, a successful COVID-19 vaccine is vulnerable to weakening upon mutation of the virus and will not protect against future novel viral outbreaks. Our universal vaccine technology is designed to protect against any type of viral infection without the requirement to have prior knowledge of the viral structure and is specifically designed to work in the weakened senescent immune systems of the elderly and frail."
The Phase I/II clinical trial will accrue 40 healthy adults over age 65. Volunteers will receive five (5) intradermal injections of AlloStim® over 14 days. Blood samples will be collected prior to injection and at 30 days, 6 months and 1 year after injection. The blood will be challenged in the laboratory with a panel of live viruses, including the COVID-19 virus and influenza viruses in order to determine if the remodeled immune system can suppress the propagation of these viruses in cultures of human endothelial cells from the respiratory tract.
Details of the clinical trial can be found on the National Institutes of Health ClinicalTrials.gov registry: ClinicalTrials.gov Identifier: NCT04441047
The universal viral protection mechanism has been reversed engineered from the immune response that results in asymptomatic viral clearance in youthful individuals. Using a novel, patent-pending technology called "allo-priming", the youthful immune response is imprinted upon the elderly immune system so that it can be ready to be activated upon encounter with any virus. The mechanism creates conditions for an "in-situ" vaccine providing viral-specific protection and memory to prevent re-infection from the same virus. The novel mechanism has been described in a peer-reviewed article published in the Journal of Translational Medicine which can be viewed by following this link.
AlloStim® is derived from precursor cells purified from the blood of healthy donors. The Company will be working to scale up and automate the production process in parallel with on-going clinical trials so that upon demonstration of safety and efficacy, the vaccine can be quickly scaled-up to quantities necessary to protect the elderly population. Today, there is estimated to be more than 46 million adults age 65 and older living in the USA.
Media Contact:
Dr. Michael Har-Noy
Phone: 1-760-216-7494
email: harnoy@immunovative.com
Related Images
Mirror Biologics
Mirror Biologics, Inc (Phoenix) is the commercial development arm of Immunovative Therapies, Ltd. (Israel)
Related Links
Website
SOURCE Immunovative Therapies, Ltd.
$EAIN Merger coming with Mirror Biologics, Inc on 10/29/2020
NVSOS Name changes happened today
https://www.fundable.com/mirror-biologics
Active Clinical Trial:
https://clinicaltrials.gov/ct2/show/NCT04441047?term=NCT04441047&draw=2&rank=1
Latest news:
Immunovative Therapies and Mirror Biologics Announce US FDA Clearance of a Universal Anti-Viral Vaccine Phase I/II Clinical Trial for Healthy Elderly Adults
https://www.prnewswire.com/il/news-releases/immunovative-therapies-and-mirror-biologics-announce-us-fda-clearance-of-a-universal-anti-viral-vaccine-phase-iii-clinical-trial-for-healthy-elderly-adults-301081793.html
JERUSALEM and PHOENIX, June 23, 2020 /PRNewswire/ -- Mirror Biologics, Inc. (Phoenix, AZ), the commercial development arm of Immunovative Therapies, Ltd. (Jerusalem, IL) (together "the Company"), a clinical-stage company specialized in the development, manufacturing and clinical translation of next-generation immunotherapy drugs where the active ingredients are living immune cells, today announced that the U.S. Food and Drug Administration (FDA) has cleared our Phase I/II universal virus vaccine clinical trial under the Company's second active Investigational New Drug (IND) application enabling use of the Company's lead experimental drug, AlloStim®, for testing as an anti-viral prophylaxis drug.
AlloStim® is an off-the-shelf, non-genetically manipulated, patented living immune cell with multiple immunodulatory properties, currently being tested under a separate IND as a therapeutic vaccine for chemotherapy-refractory metastatic cancers.
This Phase I/II trial is believed to be the first anti-viral vaccine in clinical development that is specifically targeted to protect the elderly. The elderly are the most vulnerable in our society to the severe and lethal effects of respiratory viral infections which cause disease complications such as pneumonia. Pneumonia is the single most common cause of death from infectious disease in those over 65 years old. The chance that a COVID-19 patient will develop symptoms severe enough to require hospitalization and respiratory support rises sharply with age and the death rate due to COVID-19 is disproportionately higher in our senior citizens.
Dr. Michael Har-Noy, founder and CEO stated: "We are pleased to have FDA clearance of our novel universal viral vaccine clinical trial targeted to healthy adults over 65 years old. There is a large unmet need to protect the elderly from the devastating effects of respiratory viral infection. If we can protect the elderly from COVID-19, economies can open safely and herd immunity can be allowed to develop without an alarming increase in death rate. Even if a COVID-19 vaccine is developed, it is likely, as with influenza vaccines, that it will be less effective in the elderly where protection is most needed. In addition, a successful COVID-19 vaccine is vulnerable to weakening upon mutation of the virus and will not protect against future novel viral outbreaks. Our universal vaccine technology is designed to protect against any type of viral infection without the requirement to have prior knowledge of the viral structure and is specifically designed to work in the weakened senescent immune systems of the elderly and frail."
The Phase I/II clinical trial will accrue 40 healthy adults over age 65. Volunteers will receive five (5) intradermal injections of AlloStim® over 14 days. Blood samples will be collected prior to injection and at 30 days, 6 months and 1 year after injection. The blood will be challenged in the laboratory with a panel of live viruses, including the COVID-19 virus and influenza viruses in order to determine if the remodeled immune system can suppress the propagation of these viruses in cultures of human endothelial cells from the respiratory tract.
Details of the clinical trial can be found on the National Institutes of Health ClinicalTrials.gov registry: ClinicalTrials.gov Identifier: NCT04441047
The universal viral protection mechanism has been reversed engineered from the immune response that results in asymptomatic viral clearance in youthful individuals. Using a novel, patent-pending technology called "allo-priming", the youthful immune response is imprinted upon the elderly immune system so that it can be ready to be activated upon encounter with any virus. The mechanism creates conditions for an "in-situ" vaccine providing viral-specific protection and memory to prevent re-infection from the same virus. The novel mechanism has been described in a peer-reviewed article published in the Journal of Translational Medicine which can be viewed by following this link.
AlloStim® is derived from precursor cells purified from the blood of healthy donors. The Company will be working to scale up and automate the production process in parallel with on-going clinical trials so that upon demonstration of safety and efficacy, the vaccine can be quickly scaled-up to quantities necessary to protect the elderly population. Today, there is estimated to be more than 46 million adults age 65 and older living in the USA.
Media Contact:
Dr. Michael Har-Noy
Phone: 1-760-216-7494
email: harnoy@immunovative.com
Related Images
Mirror Biologics
Mirror Biologics, Inc (Phoenix) is the commercial development arm of Immunovative Therapies, Ltd. (Israel)
Related Links
Website
SOURCE Immunovative Therapies, Ltd.
$EAIN Merger coming with Mirror Biologics, Inc on 10/29/2020
https://www.fundable.com/mirror-biologics
Active Clinical Trial:
https://clinicaltrials.gov/ct2/show/NCT04441047?term=NCT04441047&draw=2&rank=1
Immunovative Therapies and Mirror Biologics Announce US FDA Clearance of a Universal Anti-Viral Vaccine Phase I/II Clinical Trial for Healthy Elderly Adults
https://www.prnewswire.com/il/news-releases/immunovative-therapies-and-mirror-biologics-announce-us-fda-clearance-of-a-universal-anti-viral-vaccine-phase-iii-clinical-trial-for-healthy-elderly-adults-301081793.html
JERUSALEM and PHOENIX, June 23, 2020 /PRNewswire/ -- Mirror Biologics, Inc. (Phoenix, AZ), the commercial development arm of Immunovative Therapies, Ltd. (Jerusalem, IL) (together "the Company"), a clinical-stage company specialized in the development, manufacturing and clinical translation of next-generation immunotherapy drugs where the active ingredients are living immune cells, today announced that the U.S. Food and Drug Administration (FDA) has cleared our Phase I/II universal virus vaccine clinical trial under the Company's second active Investigational New Drug (IND) application enabling use of the Company's lead experimental drug, AlloStim®, for testing as an anti-viral prophylaxis drug.
AlloStim® is an off-the-shelf, non-genetically manipulated, patented living immune cell with multiple immunodulatory properties, currently being tested under a separate IND as a therapeutic vaccine for chemotherapy-refractory metastatic cancers.
This Phase I/II trial is believed to be the first anti-viral vaccine in clinical development that is specifically targeted to protect the elderly. The elderly are the most vulnerable in our society to the severe and lethal effects of respiratory viral infections which cause disease complications such as pneumonia. Pneumonia is the single most common cause of death from infectious disease in those over 65 years old. The chance that a COVID-19 patient will develop symptoms severe enough to require hospitalization and respiratory support rises sharply with age and the death rate due to COVID-19 is disproportionately higher in our senior citizens.
Dr. Michael Har-Noy, founder and CEO stated: "We are pleased to have FDA clearance of our novel universal viral vaccine clinical trial targeted to healthy adults over 65 years old. There is a large unmet need to protect the elderly from the devastating effects of respiratory viral infection. If we can protect the elderly from COVID-19, economies can open safely and herd immunity can be allowed to develop without an alarming increase in death rate. Even if a COVID-19 vaccine is developed, it is likely, as with influenza vaccines, that it will be less effective in the elderly where protection is most needed. In addition, a successful COVID-19 vaccine is vulnerable to weakening upon mutation of the virus and will not protect against future novel viral outbreaks. Our universal vaccine technology is designed to protect against any type of viral infection without the requirement to have prior knowledge of the viral structure and is specifically designed to work in the weakened senescent immune systems of the elderly and frail."
The Phase I/II clinical trial will accrue 40 healthy adults over age 65. Volunteers will receive five (5) intradermal injections of AlloStim® over 14 days. Blood samples will be collected prior to injection and at 30 days, 6 months and 1 year after injection. The blood will be challenged in the laboratory with a panel of live viruses, including the COVID-19 virus and influenza viruses in order to determine if the remodeled immune system can suppress the propagation of these viruses in cultures of human endothelial cells from the respiratory tract.
Details of the clinical trial can be found on the National Institutes of Health ClinicalTrials.gov registry: ClinicalTrials.gov Identifier: NCT04441047
The universal viral protection mechanism has been reversed engineered from the immune response that results in asymptomatic viral clearance in youthful individuals. Using a novel, patent-pending technology called "allo-priming", the youthful immune response is imprinted upon the elderly immune system so that it can be ready to be activated upon encounter with any virus. The mechanism creates conditions for an "in-situ" vaccine providing viral-specific protection and memory to prevent re-infection from the same virus. The novel mechanism has been described in a peer-reviewed article published in the Journal of Translational Medicine which can be viewed by following this link.
AlloStim® is derived from precursor cells purified from the blood of healthy donors. The Company will be working to scale up and automate the production process in parallel with on-going clinical trials so that upon demonstration of safety and efficacy, the vaccine can be quickly scaled-up to quantities necessary to protect the elderly population. Today, there is estimated to be more than 46 million adults age 65 and older living in the USA.
Media Contact:
Dr. Michael Har-Noy
Phone: 1-760-216-7494
email: harnoy@immunovative.com
Related Images
Mirror Biologics
Mirror Biologics, Inc (Phoenix) is the commercial development arm of Immunovative Therapies, Ltd. (Israel)
Related Links
Website
SOURCE Immunovative Therapies, Ltd.
ill update the ibox in a couple of minute with all the DD i was able to find
looks like a solid company that doesn't need pumping. I think it will move slowly on its own.
this could be his bigger merger till date. Is a real company with a FDA clinical trial for a covid vaccine at 75,000 share float. Could hit $10+
$EAIN Mirror Biologics Announce US FDA Clearance of a Universal Anti-Viral Vaccine. Could this be the biggest David Lazar merger? I don't like pumping, but really has Nasdaq potential.
https://prnewswire.com/il/news-releases/immunovative-therapies-and-mirror-biologics-announce-us-fda-clearance-of-a-universal-anti-viral-vaccine-phase-iii-clinical-trial-for-healthy-elderly-adults-301081793.html
https://fundable.com/mirror-biologics
Yup! finally!
good question. I don't know. The meeting is to settle stuff. so Im guessing they just need majority shareholders.
today. A-19-803941-C
https://www.clarkcountycourts.us/Portal/Case/CaseDetail?eid=V8sgXUcWPaanXml9wZHpsw2&tabIndex=3
https://www.clarkcountycourts.us/Portal/DocumentViewer/Index/_I3vPiCkabnUEH6xV26-xec6O-bgF9KbWqDogHOyk6_cCu4r_dNu2ebW7BC0HGwUEmmJT_wNL3DcyPgWPGvCdgSefHed7gb-la6_7TFEI3nj0C1aD8FqGQuXzN3y9-8d0
If Dixon comply with that timeline. They will reinstated in Nevada within 30 days. Hold a shareholder meeting in within 3 month to settle everything for a merger in the future.
nice looking Daily on very low volume. quietly going up
Lets see if they file anything soon to cure sec delinquent and get a merger done.
Attorney letter . I think it will come next week.
Forum can deliver a range of benefits to our potential merger partner, including:
A flexible funding source through a unique structure that can be tailored to the company’s specific needs
Cash consideration to existing owners at the time of merger
Retained ownership for current shareholders; with the ability to retain significant equity upside and the ability to retain control of the public company post merger
Access to new sources of capital and public currency (listed stock) to fund expansion, make acquisitions or pay down debt
Public valuation without the restrictive, time consuming, costly and uncertain IPO process
Exposure to public investor community via a NASDAQ listing
Operational guidance and support to enhance growth and value creation
Strategic planning and governance as a public company
Access to Forum’s Management Team and Board of Directors’ breadth of expertise
Our team offers:
A team of experienced public market participants who can assist in the transition from private company to public company status
Experience across multiple industries, including Consumer Products, Retail, Distribution, Energy, Financial Services, Industrial, Telecom, Media and Technology
Success building successful companies
Experience sourcing and closing acquisitions
Capital markets execution capabilities
Access to a deep and varied network of senior business leaders and influencers
We intend to focus on companies which have the following characteristics:
$500 million to $2 billion or more in enterprise value
North American based company
Robust outlook for long-term growth
Recurring revenues
What’s important to us:
Strong, driven, experienced management team
A clear understanding of their market and growth strategy
Industries that have strong barriers to entry
Scalable, capital efficient business model
Opportunities for growth, both organically and through acquisition
Sustainable competitive advantage in an attractive industry
Forum Merger III Corporation is a Special Purpose Acquisitions Company (SPAC) that went public for the purpose of merging with a private company, which will benefit from our investment and strategic support, to create substantial value over time.
Forum has raised $250 million in capital and has the ability to raise additional capital through the issuance of equity and debt securities. The capital will be used as part of the merger consideration and as growth capital.
Blank check under $10. Now that FMCI merger with Tattoo Chef is completed. This could be the next one to go. I have 1,000 shares of it long term.
He is part of CTYX. CTYX run from trips to .03+ and went from grey to pink current. He brings great value, takes time, but I like it
Barry A Ginsberg revealed to be owner is the new thing. We knew about Green Life, but no one knew green life belong to him. You are going away from my point.
he still holds the controlling interest. In the latest filing just his company name is listed “Green Life” Yesterday AH filing was the first time that his name was disclose as the owner of Green Life. That is that new part. No one knew till now that he is involved in WSGF.
Yes but the name of the owner of Green Life was never revealed. Yesterday AH filing was the first time they listed they wrote the name Barry A Ginsberg
Turns out that Barry A Ginsberg of $CTYX is the owner of $WSGF! His name was never disclosed in previous filing. This is turning very interesting now.
Filing released After Hours today
https://backend.otcmarkets.com/otcapi/company/financial-report/260373/content
$WSGF Turns out that Barry A Ginsberg of $CTYX is the owner of $WSGF! His name was never disclosed in previous filing. This is turning very interesting now.
Filing released After Hours today
https://backend.otcmarkets.com/otcapi/company/financial-report/260373/content
$WSGF Turns out that Barry A Ginsberg of $CTYX is the owner of $WSGF! His name was never disclosed in previous filing. This is turning very interesting now.
Filing released After Hours today
https://backend.otcmarkets.com/otcapi/company/financial-report/260373/content
how are you enjoying CNGT! easy stuff.
Are they trying to pull another 2016 election move to dollars?
that fill is looking good
nop. my avg is .0068 lol
I don't use price targets. I trade stuff using the charts. 5 minutes to daily depending on the catalyst and my entry. For ATVK im on freebs (I took out my initial investment and running just on gains).
In long term none dilutive plays I use the 30 minute chart and the 50MA line (purple). As long as the 50ma keeps moving up and the price stays about it. it will be good.
If it where something very volatile ill just buy and sell the macd crosses in the 5 or 30 minute charts.
Because it will be granted in less than month. 11/09/2020 Motion
https://www.clarkcountycourts.us/Portal/Case/CaseDetail?eid=WbPak7PMZshESRPOdLC0cQ2&tabIndex=3
great 1st day!
11/09/2020 Motion
Judicial Officer
Denton, Mark R.
Hearing Time
9:00 AM
Comment
Motion for Appointment of Custodian
Yesterday After hours. So technically today yea